Dr. Nagi Idris
Dr. Nagi Idris graduated from Alrab Medical University, Benghazi, Libya in 1996 with a BSc in Pharmaceutical sciences before relocating to University of Bradford to study for PhD (2005) in Psychopharmacology.
Following a 4-year postdoctoral position, he was appointed as a Psychopharmacology Lecturer in the University of Bradford and a scientist in schizophrenia and Alzheimer's disease research projects, now managed by b-neuro™, UK. He contributed significantly to the development of new methods for testing novel drug therapy for patients suffering from schizophrenia and related disorders. Participation in internal and external networks; in particular collaborations with an extensive group of academic and industrial groups in the wider field of schizophrenia research, including GlaxoSmithKline, Lundbeck, Neurosearch, Merz, Forest and Takeda, Johnson and Johnson, Rocha, and Pfizer. He regularly presents data at international (US + Europe) conferences in the form of posters and oral presentations. He has been awarded numerous awards for bursaries and travel awards to attend international conferences.
As an early career scientist he has a rapidly growing publication record, with 10 published peer-reviewed papers in high ranking journals and over 30 abstracts. In addition, he is regularly requested to peer-review manuscripts for publications in various high ranking journals. Society Membership of: Schizophrenia International Research Society, European College of Neuropsychopharmacology, Society for Neuroscience, Federation of European Neuroscience Societies, British Neuroscience Association and British Association for Psychopharmacology.
< < Back to Members
Following a 4-year postdoctoral position, he was appointed as a Psychopharmacology Lecturer in the University of Bradford and a scientist in schizophrenia and Alzheimer's disease research projects, now managed by b-neuro™, UK. He contributed significantly to the development of new methods for testing novel drug therapy for patients suffering from schizophrenia and related disorders. Participation in internal and external networks; in particular collaborations with an extensive group of academic and industrial groups in the wider field of schizophrenia research, including GlaxoSmithKline, Lundbeck, Neurosearch, Merz, Forest and Takeda, Johnson and Johnson, Rocha, and Pfizer. He regularly presents data at international (US + Europe) conferences in the form of posters and oral presentations. He has been awarded numerous awards for bursaries and travel awards to attend international conferences.
As an early career scientist he has a rapidly growing publication record, with 10 published peer-reviewed papers in high ranking journals and over 30 abstracts. In addition, he is regularly requested to peer-review manuscripts for publications in various high ranking journals. Society Membership of: Schizophrenia International Research Society, European College of Neuropsychopharmacology, Society for Neuroscience, Federation of European Neuroscience Societies, British Neuroscience Association and British Association for Psychopharmacology.
< < Back to Members